Advertisement

Advertisement

Home / Business and Economy / Biotech Firm Metsera Doubles in Value After Analyst Upgrade

Biotech Firm Metsera Doubles in Value After Analyst Upgrade

Summary

  • Metsera stock rises 5% after Leerink Partners initiates coverage with "outperform" rating
  • Leerink sees Metsera's obesity drug platform as a key advantage over competitors
  • Kingsoft Cloud jumps 13% on AI-driven growth and improving margins
Biotech Firm Metsera Doubles in Value After Analyst Upgrade

In the latest market moves, several companies have seen significant stock price changes. Biotech firm Metsera rose 5% after Leerink Partners initiated coverage with an "outperform" rating, predicting the stock could double in value. Leerink cited Metsera's platform and pipeline of novel obesity-focused therapeutics as key advantages over competing assets.

Elsewhere, cloud provider Kingsoft Cloud jumped more than 13% after an upgrade to "buy" from Bank of America. The bank noted that AI is acting as a key growth driver for Kingsoft's public cloud services, contributing 39% of revenue in the second quarter of 2025. Improving margins were also cited as a positive factor.

Additionally, insurer Brighthouse Financial surged over 11% after reports that private equity firm Aquarian was in talks to raise funds for a potential takeover of the company.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Advertisement

Advertisement

FAQ

Metsera's platform and pipeline are focused on novel obesity-based therapeutics, which the company's analysts say offer key advantages over competing assets.
According to Bank of America, AI is contributing 39% of Kingsoft Cloud's public cloud services revenue in the second quarter of 2025.
Private equity firm Aquarian is reportedly in talks to raise funds for a potential takeover of insurer Brighthouse Financial.

Read more news on